Taking Cancer Treatment To A New Level (OTC:PVCT)
StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including one nearly entering Phase II for Breast Cancer, one of the largest target markets worldwide and seeking “compassionate use” in Australia and USA, look for Provectus to make a splash within the next couple of months.
They are developing and testing one of the most exciting anti- cancer compounds. It has been demonstrating significant effectiveness against Melanoma in Phase 2 clinical trials and it offers promising treatment for breast, liver and other solid tumor based metastatic cancers. The compound developed by Provectus, known as PV-10, is a liquid that is injected directly into certain types of tumors and has been shown to obliterate many of them with little or no toxic side effects.
Further, Provectus researchers have also seen something which was initially unexpected. Injection of the compound often causes a reduction in non-targeted tumors as well as the ones that have been directly injected. This surprising systemic effect is called the “bystander effect”. It also suggests the emergence of a powerful and safe systemic anti-metastatic treatment.
The primary ingredient in the compound, known as PV-10, has a long history of use as a “maker die” and is known to have few, if any, toxic side effects in humans and other mammals. The current trials have been confirming the general safety of the compound. Provectus is moving as quickly as it can, without sacrificing the integrity of the study, to complete its Phase 2 clinical trials on Melanoma, to move forward on Phase 1 trial in liver and perhaps Phase 2 in breast cancer and to open up PV-10 for “compassionate use” in both Australia and the US. A compassionate use application is one where other cancers are treated beyond any FDA protocol.
About Provectus Pharmaceuticals
Provectus Pharmaceuticals, Inc., is a development-stage biopharmaceutical company that is focusing on developing invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including recurrent breast carcinoma, metastatic melanoma and liver cancer. The Company through its subsidiaries develops, licenses, markets and plans to sell products in three sectors of the healthcare industry, which include Over-the-counter products (OTC products), Prescription drugs and Medical device systems. The Company conducts its business through its seven wholly owned subsidiaries, namely Xantech Pharmaceuticals, Inc., Pure-ific Corporation, Provectus Biotech, Inc., Provectus Devicetech, Inc., Provectus Imaging, Inc., IP Tech, Inc. and Provectus Pharmatech, Inc. The Company’s prescription drug products encompass the areas of dermatology and oncology and involve several types of small molecule-based drugs.
The full special report on the company appears today at http://www.stockshaven.com/taking-cancer-treatment-to-a-new-level-otcpvct/
Disclosure: Position in PVCT
To feature your publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at firstname.lastname@example.org or visit http://www.stockshaven.com/ir_contract/ for more info
About StocksHaven Investments
StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.
For more financial and investment news, visit www.StocksHaven.com
Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
- Contact Information
- Michael Vlaicu
- Founder and Lead Investment Analyst
- StocksHaven Investments
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.